跳至主要内容
临床试验/NCT06108934
NCT06108934招募中不适用

A Prospective, Pre-market, Multi-center Evaluation of the Clinical Outcomes of the Insignia Hip Stem in Total Hip Arthroplasty (THA)

Stryker Australia Pty Ltd.2 个研究点 分布在 1 个国家目标入组 313 人开始时间: 2024年2月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
313
试验地点
2
主要终点
Implant survivorship

研究概览

简要总结

The purpose of this study is to evaluate the survivorship (revision rates) and patient reported outcomes (PROMs) following implantation of the Insignia hip stem in patients undergoing cementless total hip replacement surgery compared to currently available stems used for the same type of surgery.

It is hypothesised the 2-year survivorship of the Insignia stem is noninferior to the benchmark survivorship of similar stems used in the same type of surgery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient has signed the study specific, Human Research Ethics Committee (HREC) approved, Patient Information Consent Form for the use of the study device
  • Primary non-inflammatory degenerative joint disease (including osteoarthritis or avascular necrosis) and/or rheumatoid arthritis
  • The patient is a candidate for a primary cementless THA.
  • Patients who are informed of the conditions of the study and are willing to participate for the length of the prescribed follow-up period.

排除标准

  • Active or suspected latent infection in or about the affected hip joint and the time of study device implantation.
  • Any mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure or complications in post-operative care.
  • Has bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the prosthesis.
  • Is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. >30 days.)
  • Requires revision THA or hip fusion to the affected joint.
  • Has known sensitivity to device materials.
  • Any involvement in an active Workers' Compensation investigation

结局指标

主要结局

Implant survivorship

时间窗: 2 years post-operatively

Implant survivorship using cumulative percent revision (CPR) of the Insignia hip stem, for any reason.

次要结局

  • Hip Disability and Osteoarthritis Outcome Score (HOOS-12).(Pre-operatively and 6 months, 12 months and 2 years post-operatively)
  • Hip and lower back pain VAS(Pre-operatively and 6 months, 12 months and 2 years post-operatively)
  • EQ-5D-5L(Pre-operatively and 6 months, 12 months and 2 years post-operatively)
  • Oxford Hip Score(Pre-operatively and 6 months, 12 months and 2 years post-operatively)
  • Femoral fracture(2 years post-operatively)
  • Forgotten Joint Score (FJS)(Pre-operatively and 6 months, 12 months and 2 years post-operatively)
  • Complications(Collected as they arise post-operatively. Reported as number within 6 months, 12 months and 2 years post-operatively.)
  • Mortality(1 and 2 years post-operatively)
  • CPR for stem loosening(2 years post-operatively)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

A Prospective, Pre-market, Multi-center Study of... | 临床试验